A structured coordination will help in the development of the right products.
As stated by recent strategic reports (“Global biomaterial market” – Research&Markets, May 2011), the European biomaterial products market is expected to grow to $19.7 billion in 2015 from $8.9 billion in 2009 with a progression of 14.6% from 2010 to 2015. The orthopaedic biomaterial product market is the dominant segment, standing at an estimated $3.5 billion in 2010. Therefore, R&D increasing the performance and reducing the prices of the products will obviously benefit to manufacturers, surgeons and of course, patients. The competitivity of European companies will be enhanced.
The enhanced communication with surgeons through the COST Action meetings will be beneficial for researchers and industrials to learn how to manage the strict medical rules and regulatory issues affecting the biomaterial products.
New strategies of enhancement of the biocompatibility and use of biocidal molecules other than antibiotics to prevent the emergence of multidrug resistant strains by the functionalization of the implant.
